Kimberly S Erler1, Rui Wu1, Julie A DiCarlo1, Marina F Petrilli1, Perman Gochyyev1, Leigh R Hochberg1, Steven A Kautz1, Lee H Schwamm1, Steven C Cramer1, Seth P Finklestein1, David J Lin1. 1. From the Center for Neurotechnology and Neurorecovery (K.S.E., R.W., J.A.D., L.R.H., D.J.L.), Division of Neurocritical Care (L.R.H, D.J.L.), Stroke Service (L.R.H., L.H.S., S.P.F., D.J.L.), Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston; Department of Occupational Therapy (K.S.E.), Massachusetts General Hospital, Boston; School of Health and Rehabilitation Sciences (K.S.E., M.F.P., P.G., D.J.L.), MGH Institute of Health Professions, Boston, MA; VA RR&D Center for Neurorestoration and Neurotechnology (L.R.H., D.J.L.), VA Medical Center, Providence, RI; School of Health Sciences and Research (S.A.K.), Medical University of South Carolina, Charleston; Ralph H. Johnson VA Medical Center (S.A.K.), Charleston, SC; Department of Neurology (S.C.C.), University of California, Los Angeles; California Rehabilitation Institute (S.C.C.), Los Angeles.
Abstract
BACKGROUND AND OBJECTIVES: Precise measurement of outcomes is essential for stroke trials and clinical care. Prior research has highlighted conceptual differences between global outcome measures such as the modified Rankin Scale (mRS) and domain-specific measures (e.g., motor, sensory, language or cognitive function). This study related motor phenotypes to the mRS, specifically aiming to determine whether mRS levels distinguish motor impairment and function phenotypes, and to compare mRS outcomes to meaningful changes in impairment and function from acute to subacute recovery after stroke. METHODS: Patients with upper extremity weakness after ischemic stroke were assessed with a battery of impairment and functional measures within the first week and at 90 days after stroke. Impairment and functional outcomes were examined in relation to 90-day mRS scores. Clinically meaningful changes in motor impairment, activities of daily living, and mobility were examined in relation to 90-day mRS score. RESULTS: In this cohort of 73 patients with stroke, impairment and functional outcomes were associated with 90-day mRS scores but showed substantial variability within individual mRS levels: within mRS level 2, upper extremity impairment ranged from near hemiplegia (with an upper extremity Fugl-Meyer score 8) to no deficits (upper extremity Fugl-Meyer score 66). Overall, there were few differences in impairment and functional outcomes between adjacent mRS levels. While some outcome measures were significantly different between mRS levels 3 and 4 (Nine-Hole Peg, Leg Motor, gait velocity, Timed Up and Go, NIH Stroke Scale, and Barthel Index), none of the outcome measures differed between mRS levels 1 and 2. Fugl-Meyer and grip strength were not different between any adjacent mRS levels. A substantial number of patients experienced clinically meaningful changes in impairment and function in the first 90 days after stroke but did not achieve good mRS outcome (mRS score ≤ 2). DISCUSSION: The mRS broadly relates to domain-specific outcomes after stroke, confirming its established value in stroke trials, but it does not precisely distinguish differences in impairment and function, nor does it sufficiently capture meaningful clinical changes across impairment, activities of daily living status, and mobility. These findings underscore the potential utility of incorporating detailed phenotypic measures along with the mRS in future stroke trials.
BACKGROUND AND OBJECTIVES: Precise measurement of outcomes is essential for stroke trials and clinical care. Prior research has highlighted conceptual differences between global outcome measures such as the modified Rankin Scale (mRS) and domain-specific measures (e.g., motor, sensory, language or cognitive function). This study related motor phenotypes to the mRS, specifically aiming to determine whether mRS levels distinguish motor impairment and function phenotypes, and to compare mRS outcomes to meaningful changes in impairment and function from acute to subacute recovery after stroke. METHODS: Patients with upper extremity weakness after ischemic stroke were assessed with a battery of impairment and functional measures within the first week and at 90 days after stroke. Impairment and functional outcomes were examined in relation to 90-day mRS scores. Clinically meaningful changes in motor impairment, activities of daily living, and mobility were examined in relation to 90-day mRS score. RESULTS: In this cohort of 73 patients with stroke, impairment and functional outcomes were associated with 90-day mRS scores but showed substantial variability within individual mRS levels: within mRS level 2, upper extremity impairment ranged from near hemiplegia (with an upper extremity Fugl-Meyer score 8) to no deficits (upper extremity Fugl-Meyer score 66). Overall, there were few differences in impairment and functional outcomes between adjacent mRS levels. While some outcome measures were significantly different between mRS levels 3 and 4 (Nine-Hole Peg, Leg Motor, gait velocity, Timed Up and Go, NIH Stroke Scale, and Barthel Index), none of the outcome measures differed between mRS levels 1 and 2. Fugl-Meyer and grip strength were not different between any adjacent mRS levels. A substantial number of patients experienced clinically meaningful changes in impairment and function in the first 90 days after stroke but did not achieve good mRS outcome (mRS score ≤ 2). DISCUSSION: The mRS broadly relates to domain-specific outcomes after stroke, confirming its established value in stroke trials, but it does not precisely distinguish differences in impairment and function, nor does it sufficiently capture meaningful clinical changes across impairment, activities of daily living status, and mobility. These findings underscore the potential utility of incorporating detailed phenotypic measures along with the mRS in future stroke trials.
Authors: Julie Bernhardt; Kathryn S Hayward; Gert Kwakkel; Nick S Ward; Steven L Wolf; Karen Borschmann; John W Krakauer; Lara A Boyd; S Thomas Carmichael; Dale Corbett; Steven C Cramer Journal: Int J Stroke Date: 2017-07 Impact factor: 5.266
Authors: Vladimir Hachinski; Geoffrey A Donnan; Philip B Gorelick; Werner Hacke; Steven C Cramer; Markku Kaste; Marc Fisher; Michael Brainin; Alastair M Buchan; Eng H Lo; Brett E Skolnick; Karen L Furie; Graeme J Hankey; Miia Kivipelto; John Morris; Peter M Rothwell; Ralph L Sacco; Sidney C Smith; Yulun Wang; Alan Bryer; Gary A Ford; Costantino Iadecola; Sheila C O Martins; Jeff Saver; Veronika Skvortsova; Mark Bayley; Martin M Bednar; Pamela Duncan; Lori Enney; Seth Finklestein; Theresa A Jones; Lalit Kalra; Jeff Kleim; Ralph Nitkin; Robert Teasell; Cornelius Weiller; Bhupat Desai; Mark P Goldberg; Wolf-Dieter Heiss; Osmo Saarelma; Lee H Schwamm; Yukito Shinohara; Bhargava Trivedi; Nils Wahlgren; Lawrence K Wong; Antoine Hakim; Bo Norrving; Stephen Prudhomme; Natan M Bornstein; Stephen M Davis; Larry B Goldstein; Didier Leys; Jaakko Tuomilehto Journal: Cerebrovasc Dis Date: 2010-05-24 Impact factor: 2.762
Authors: G Kwakkel; E E H van Wegen; J H Burridge; C J Winstein; L E H van Dokkum; M Alt Murphy; M F Levin; J W Krakauer Journal: Neurorehabil Neural Repair Date: 2019-10-29 Impact factor: 3.919
Authors: Anna K Bonkhoff; Teresa Ullberg; Martin Bretzner; Sungmin Hong; Markus D Schirmer; Robert W Regenhardt; Kathleen L Donahue; Marco J Nardin; Adrian V Dalca; Anne-Katrin Giese; Mark R Etherton; Brandon L Hancock; Steven J T Mocking; Elissa C McIntosh; John Attia; John W Cole; Amanda Donatti; Christoph J Griessenauer; Laura Heitsch; Lukas Holmegaard; Katarina Jood; Jordi Jimenez-Conde; Steven J Kittner; Robin Lemmens; Christopher R Levi; Caitrin W McDonough; James F Meschia; Chia-Ling Phuah; Stefan Ropele; Jonathan Rosand; Jaume Roquer; Tatjana Rundek; Ralph L Sacco; Reinhold Schmidt; Pankaj Sharma; Agnieszka Slowik; Alessandro Sousa; Tara M Stanne; Daniel Strbian; Turgut Tatlisumak; Vincent Thijs; Achala Vagal; Daniel Woo; Ramin Zand; Patrick F McArdle; Bradford B Worrall; Christina Jern; Arne G Lindgren; Jane Maguire; Ona Wu; Petrea Frid; Natalia S Rost; Johan Wasselius Journal: Front Neurosci Date: 2022-08-25 Impact factor: 5.152